FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1497180632> ?p ?o ?g. }

• W1497180632 endingPage "487" @default.
• W1497180632 startingPage "479" @default.
• W1497180632 abstract "ABSTRACT It is believed that glycogen synthase kinase‐3 hyperphosphorylates tau protein in progressive supranuclear palsy (PSP). The Tau Restoration on PSP (TAUROS) trial assessed the glycogen synthase kinase‐3 inhibitor tideglusib as potential treatment. For the magnetic resonance imaging (MRI) substudy reported here, we assessed the progression of brain atrophy. TAUROS was a multinational, phase 2, double‐blind, placebo‐controlled trial in patients with mild‐to‐moderate PSP who were treated with oral tideglusib (600 mg or 800 mg daily) or with placebo for 1 year. A subset of patients underwent baseline and 52‐week MRI. Automated, observer‐independent, atlas‐based, and mask‐based volumetry was done on high‐resolution, T1‐weighted, three‐dimensional data. For primary outcomes, progression of atrophy was compared both globally (brain, cerebrum) and regionally (third ventricle, midbrain, pons) between the active and placebo groups (Bonferroni correction). For secondary outcomes, 15 additional brain structures were explored (Benjamini & Yekutieli correction). In total, MRIs from 37 patient were studied (placebo group, N = 9; tideglusib 600 mg group, N = 19; tideglusib 800 mg group, N = 9). The groups compared well in their demographic characteristics. Clinical results showed no effect of tideglusib over placebo. Progression of atrophy was significantly lower in the active group than in the placebo group for the brain (mean ± standard error of the mean: −1.3% ± 1.4% vs. −3.1% ± 2.3%, respectively), cerebrum (−1.3% ± 1.5% vs. −3.2% ± 2.1%, respectively), parietal lobe (−1.6% ± 1.9% vs. −4.1% ± 3.0%, respectively), and occipital lobe (−0.3% ± 1.8% vs. −2.7% ± 3.2%, respectively). A trend toward reduced atrophy also was observed in the frontal lobe, hippocampus, caudate nucleus, midbrain, and brainstem. In patients with PSP, tideglusib reduced the progression of atrophy in the whole brain, particularly in the parietal and occipital lobes. © 2014 International Parkinson and Movement Disorder Society" @default.
• W1497180632 created "2016-06-24" @default.
• W1497180632 creator A5004662410 @default.
• W1497180632 creator A5014117021 @default.
• W1497180632 creator A5020207419 @default.
• W1497180632 creator A5066934882 @default.
• W1497180632 creator A5068749612 @default.
• W1497180632 creator A5088471519 @default.
• W1497180632 creator A5089271598 @default.
• W1497180632 date "2014-01-31" @default.
• W1497180632 modified "2023-10-06" @default.
• W1497180632 title "Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial" @default.
• W1497180632 cites W1532078866 @default.
• W1497180632 cites W1954244449 @default.
• W1497180632 cites W1965278136 @default.
• W1497180632 cites W1980456750 @default.
• W1497180632 cites W1980827933 @default.
• W1497180632 cites W1987528617 @default.
• W1497180632 cites W1995377960 @default.
• W1497180632 cites W1998932116 @default.
• W1497180632 cites W2003159754 @default.
• W1497180632 cites W2018765794 @default.
• W1497180632 cites W2023996132 @default.
• W1497180632 cites W2043797799 @default.
• W1497180632 cites W2049146362 @default.
• W1497180632 cites W2106922104 @default.
• W1497180632 cites W2121046597 @default.
• W1497180632 cites W2124121545 @default.
• W1497180632 cites W2131943911 @default.
• W1497180632 cites W2136276906 @default.
• W1497180632 cites W2136557657 @default.
• W1497180632 cites W2165934826 @default.
• W1497180632 cites W2171051269 @default.
• W1497180632 doi "https://doi.org/10.1002/mds.25815" @default.
• W1497180632 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24488721" @default.
• W1497180632 hasPublicationYear "2014" @default.
• W1497180632 type Work @default.
• W1497180632 sameAs 1497180632 @default.
• W1497180632 citedByCount "126" @default.
• W1497180632 countsByYear W14971806322013 @default.
• W1497180632 countsByYear W14971806322014 @default.
• W1497180632 countsByYear W14971806322015 @default.
• W1497180632 countsByYear W14971806322016 @default.
• W1497180632 countsByYear W14971806322017 @default.
• W1497180632 countsByYear W14971806322018 @default.
• W1497180632 countsByYear W14971806322019 @default.
• W1497180632 countsByYear W14971806322020 @default.
• W1497180632 countsByYear W14971806322021 @default.
• W1497180632 countsByYear W14971806322022 @default.
• W1497180632 countsByYear W14971806322023 @default.
• W1497180632 crossrefType "journal-article" @default.
• W1497180632 hasAuthorship W1497180632A5004662410 @default.
• W1497180632 hasAuthorship W1497180632A5014117021 @default.
• W1497180632 hasAuthorship W1497180632A5020207419 @default.
• W1497180632 hasAuthorship W1497180632A5066934882 @default.
• W1497180632 hasAuthorship W1497180632A5068749612 @default.
• W1497180632 hasAuthorship W1497180632A5088471519 @default.
• W1497180632 hasAuthorship W1497180632A5089271598 @default.
• W1497180632 hasConcept C126322002 @default.
• W1497180632 hasConcept C126838900 @default.
• W1497180632 hasConcept C142724271 @default.
• W1497180632 hasConcept C143409427 @default.
• W1497180632 hasConcept C15744967 @default.
• W1497180632 hasConcept C202061045 @default.
• W1497180632 hasConcept C204787440 @default.
• W1497180632 hasConcept C27081682 @default.
• W1497180632 hasConcept C2776477761 @default.
• W1497180632 hasConcept C2781172350 @default.
• W1497180632 hasConcept C2989005 @default.
• W1497180632 hasConcept C2991744798 @default.
• W1497180632 hasConcept C71924100 @default.
• W1497180632 hasConcept C90924648 @default.
• W1497180632 hasConceptScore W1497180632C126322002 @default.
• W1497180632 hasConceptScore W1497180632C126838900 @default.
• W1497180632 hasConceptScore W1497180632C142724271 @default.
• W1497180632 hasConceptScore W1497180632C143409427 @default.
• W1497180632 hasConceptScore W1497180632C15744967 @default.
• W1497180632 hasConceptScore W1497180632C202061045 @default.
• W1497180632 hasConceptScore W1497180632C204787440 @default.
• W1497180632 hasConceptScore W1497180632C27081682 @default.
• W1497180632 hasConceptScore W1497180632C2776477761 @default.
• W1497180632 hasConceptScore W1497180632C2781172350 @default.
• W1497180632 hasConceptScore W1497180632C2989005 @default.
• W1497180632 hasConceptScore W1497180632C2991744798 @default.
• W1497180632 hasConceptScore W1497180632C71924100 @default.
• W1497180632 hasConceptScore W1497180632C90924648 @default.
• W1497180632 hasIssue "4" @default.
• W1497180632 hasLocation W14971806321 @default.
• W1497180632 hasOpenAccess W1497180632 @default.
• W1497180632 hasPrimaryLocation W14971806321 @default.
• W1497180632 hasRelatedWork W1970520913 @default.
• W1497180632 hasRelatedWork W2025580183 @default.
• W1497180632 hasRelatedWork W2039577238 @default.
• W1497180632 hasRelatedWork W2069213633 @default.
• W1497180632 hasRelatedWork W2081684908 @default.
• W1497180632 hasRelatedWork W2111829140 @default.
• W1497180632 hasRelatedWork W2124640962 @default.
• W1497180632 hasRelatedWork W2125308968 @default.

• next